Sergey B. Zhuplatov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sergey B. Zhuplatov has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Alfred K. Cheung
Division of Nephrology and Hypertension, University of Utah, Salt Lake City, Utah
3 shared publications - Donald K. Blumenthal
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA
2 shared publications Poul Strange
Integrated Medical Development, LLC , Princeton Junction, New Jersey
2 shared publicationsRong Zhou
Medpace, Inc. , Cincinnati, Ohio
2 shared publicationsSA MARIZIN
2 shared publicationsTakahisa Masaki
Veterans Affairs Salt Lake City Healthcare System, Departments of Medicine, Pharmacology & Toxicology, and Biochemistry, University of Utah, Salt Lake City, Utah, U.S.A.
2 shared publications
Latest Publications
- Open Access
- 1 January 2024
- Published by MedCrave Group Kft. in Pharmacy & Pharmacology International Journal
- Vol. 12 (6) , 210-213
Vimentin in melanoma: diagnostic and therapeutic applications. Mini-Review
Melanoma, the deadliest form of skin cancer, poses a significant global health challenge due to its high metastatic potential and resistance to conventional therapies. Vimentin, an intermediate filament protein typically expressed in mesenchymal cells, plays a crucial role in various cellular processes, including cell motility, invasion, and metastasis. Different authors discuss the scientific value of using Vimentin as the diagnostic marker for invasive types of cancer, including various kinds (oral, hematogenous, amelanotic, etc.) of Melanoma. Recently, several investigators suggested the possible clinical application of the monoclonal antibodies inhibiting Vimentin activity for vimentin-targeted tumor-specific therapy. Another approach could be developing small molecule inhibitors targeting vimentin or its interacting partners. Authors have found promising results using pannexin 1, or inhibitors of aPKC and other inhibitors of vimentin activity could reduce tumor growth in in-vivo experiments. The development of more specific and effective vimentin-targeted therapies and diagnostic approaches holds significant promise for improving the outcome of melanoma patients.
- 1 January 2024
- Published by MedCrave Group Kft. in Pharmacy & Pharmacology International Journal
- Vol. 12 (6) , 210-213
Open AccessVimentin in melanoma: diagnostic and therapeutic applications. Mini-Review
Melanoma, the deadliest form of skin cancer, poses a significant global health challenge due to its high metastatic potential and resistance to conventional therapies. Vimentin, an intermediate filament protein typically expressed in mesenchymal cells, plays a crucial role in various cellular processes, including cell motility, invasion, and metastasis. Different authors discuss the scientific value of using Vimentin as the diagnostic marker for invasive types of cancer, including various kinds (oral, hematogenous, amelanotic, etc.) of Melanoma. Recently, several investigators suggested the possible clinical application of the monoclonal antibodies inhibiting Vimentin activity for vimentin-targeted tumor-specific therapy. Another approach could be developing small molecule inhibitors targeting vimentin or its interacting partners. Authors have found promising results using pannexin 1, or inhibitors of aPKC and other inhibitors of vimentin activity could reduce tumor growth in in-vivo experiments. The development of more specific and effective vimentin-targeted therapies and diagnostic approaches holds significant promise for improving the outcome of melanoma patients.
- Open Access
- 25 October 2018
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 20 (11) , 715-724
Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial
Background: Glycated hemoglobin (HbA1c) and measures of short-term glycemia do not fully capture daily patterns in plasma glucose dynamics. This study evaluated 24-h glycemic profiles in patients with type 2 diabetes (T2D) initiated on dapagliflozin treatment using continuous glucose monitoring (CGM). Methods: This randomized double-blind placebo-controlled multicenter parallel-design 4-week study compared dapagliflozin (10 mg/d; n = 50) with placebo ( n = 50) in adult patients with T2D uncontrolled (HbA1c 7.5%–10.5%) on either stable doses of metformin monotherapy (≥1500 mg/d) or insulin (≥30 U/d with or without up to two oral antidiabetes drugs). CGM was used to measure 24-h glycemic profiles for 7 days pretreatment and during week 4 of treatment. The primary outcome was change from baseline in 24-h mean glucose (MG) at week 4. Results: The 24-h MG decreased 18.2 mg/dL with dapagliflozin and increased 5.8 mg/dL with placebo ( P < 0.001). The proportion of time spent in the target glucose range (70–180 mg/dL) increased significantly with dapagliflozin versus placebo (69.6% vs. 52.9%; P < 0.001), with a small (0.3%) increase in time spent in the hypoglycemic range (<70 mg/dL), driven by those on background insulin therapy. Dapagliflozin reduced postprandial glucose and significantly decreased overall glucose variability. Few events of symptomatic hypoglycemia occurred. The most common adverse event was urinary tract infection (6% in each treatment arm). Conclusions: Compared with placebo, dapagliflozin improved measures of glycemic control and variability as assessed by CGM. Glycemic improvements were more pronounced in the group on background metformin than those receiving basal insulin.
- 25 October 2018
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 20 (11) , 715-724
Open AccessEffects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial
Background: Glycated hemoglobin (HbA1c) and measures of short-term glycemia do not fully capture daily patterns in plasma glucose dynamics. This study evaluated 24-h glycemic profiles in patients with type 2 diabetes (T2D) initiated on dapagliflozin treatment using continuous glucose monitoring (CGM). Methods: This randomized double-blind placebo-controlled multicenter parallel-design 4-week study compared dapagliflozin (10 mg/d; n = 50) with placebo ( n = 50) in adult patients with T2D uncontrolled (HbA1c 7.5%–10.5%) on either stable doses of metformin monotherapy (≥1500 mg/d) or insulin (≥30 U/d with or without up to two oral antidiabetes drugs). CGM was used to measure 24-h glycemic profiles for 7 days pretreatment and during week 4 of treatment. The primary outcome was change from baseline in 24-h mean glucose (MG) at week 4. Results: The 24-h MG decreased 18.2 mg/dL with dapagliflozin and increased 5.8 mg/dL with placebo ( P < 0.001). The proportion of time spent in the target glucose range (70–180 mg/dL) increased significantly with dapagliflozin versus placebo (69.6% vs. 52.9%; P < 0.001), with a small (0.3%) increase in time spent in the hypoglycemic range (<70 mg/dL), driven by those on background insulin therapy. Dapagliflozin reduced postprandial glucose and significantly decreased overall glucose variability. Few events of symptomatic hypoglycemia occurred. The most common adverse event was urinary tract infection (6% in each treatment arm). Conclusions: Compared with placebo, dapagliflozin improved measures of glycemic control and variability as assessed by CGM. Glycemic improvements were more pronounced in the group on background metformin than those receiving basal insulin.
- Open Access
- 21 September 2016
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (1) , 40-48
Exenatide once weekly improved 24‐hour glucose control and reduced glycaemic variability in metformin‐treated participants with type 2 diabetes: a randomized, placebo‐controlled trial
Aim: To assess the effects of once‐weekly exenatide on 24‐hour glucose control and variability. Materials and methods: This double‐blind, placebo‐controlled trial randomized metformin‐treated adults with type 2 diabetes to once‐weekly exenatide 2.0 mg or placebo. Continuous glucose monitoring ( CGM ) was performed at baseline and weeks 4 and 10. The primary outcome was change in CGM ‐measured 24‐hour mean glucose level. Results: In the once‐weekly exenatide (n = 60) and placebo (n = 56) groups (modified intention‐to‐treat population), the baseline glycated haemoglobin ( HbA1c ) concentrations were 8.2% and 8.0%, respectively, and the fasting plasma glucose ( FPG ) concentration was 9.86 and 9.32 mmol/ L , respectively. Once‐weekly exenatide significantly (p < 0.001) reduced 24‐hour mean glucose level versus placebo (week 4, −1.44 vs −0.29 mmol/ L ; week 10, −1.71 vs −0.17 mmol/ L ), with consistent control throughout the week. Once‐weekly exenatide significantly reduced FPG and 2‐hour postprandial glucose ( PPG ) levels versus placebo at week 4 ( FPG , −1.65 vs −0.11 mmol/ L ; PPG , −1.79 vs −0.11 mmol/ L ) and week 10 ( FPG , −2.32 vs −0.28 mmol/ L ; PPG , −2.46 vs −0.33 mmol/ L ). At week 10, once‐weekly exenatide reduced the mean amplitude of glucose excursions ( MAGE ; −0.84 vs 0.16 mmol/ L ) and standard deviation (s.d.) of mean glucose (−0.35 vs 0.04 mmol/ L ). By week 10, once‐weekly exenatide‐treated participants spent more time in euglycaemia (once‐weekly exenatide, 77% vs placebo, 58%), less time in hyperglycaemia (22% vs 42%), and a similar time in hypoglycaemia (0.7% vs 0.3%). Common adverse events were injection‐site nodule (once‐weekly exenatide, 10.0% vs placebo, 0.0%), urinary tract infection (6.7% vs 8.9%) and nausea (6.7% vs 0.0%). Conclusions: In metformin‐treated participants with type 2 diabetes, once‐weekly exenatide significantly improved daily glucose control and reduced glycaemic variability at weeks 4 and 10, as shown by reductions in 24‐hour glucose, FPG and PPG levels, MAGE and s.d., and increased time spent in euglycaemia.
- 21 September 2016
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (1) , 40-48
Open AccessExenatide once weekly improved 24‐hour glucose control and reduced glycaemic variability in metformin‐treated participants with type 2 diabetes: a randomized, placebo‐controlled trial
Aim: To assess the effects of once‐weekly exenatide on 24‐hour glucose control and variability. Materials and methods: This double‐blind, placebo‐controlled trial randomized metformin‐treated adults with type 2 diabetes to once‐weekly exenatide 2.0 mg or placebo. Continuous glucose monitoring ( CGM ) was performed at baseline and weeks 4 and 10. The primary outcome was change in CGM ‐measured 24‐hour mean glucose level. Results: In the once‐weekly exenatide (n = 60) and placebo (n = 56) groups (modified intention‐to‐treat population), the baseline glycated haemoglobin ( HbA1c ) concentrations were 8.2% and 8.0%, respectively, and the fasting plasma glucose ( FPG ) concentration was 9.86 and 9.32 mmol/ L , respectively. Once‐weekly exenatide significantly (p < 0.001) reduced 24‐hour mean glucose level versus placebo (week 4, −1.44 vs −0.29 mmol/ L ; week 10, −1.71 vs −0.17 mmol/ L ), with consistent control throughout the week. Once‐weekly exenatide significantly reduced FPG and 2‐hour postprandial glucose ( PPG ) levels versus placebo at week 4 ( FPG , −1.65 vs −0.11 mmol/ L ; PPG , −1.79 vs −0.11 mmol/ L ) and week 10 ( FPG , −2.32 vs −0.28 mmol/ L ; PPG , −2.46 vs −0.33 mmol/ L ). At week 10, once‐weekly exenatide reduced the mean amplitude of glucose excursions ( MAGE ; −0.84 vs 0.16 mmol/ L ) and standard deviation (s.d.) of mean glucose (−0.35 vs 0.04 mmol/ L ). By week 10, once‐weekly exenatide‐treated participants spent more time in euglycaemia (once‐weekly exenatide, 77% vs placebo, 58%), less time in hyperglycaemia (22% vs 42%), and a similar time in hypoglycaemia (0.7% vs 0.3%). Common adverse events were injection‐site nodule (once‐weekly exenatide, 10.0% vs placebo, 0.0%), urinary tract infection (6.7% vs 8.9%) and nausea (6.7% vs 0.0%). Conclusions: In metformin‐treated participants with type 2 diabetes, once‐weekly exenatide significantly improved daily glucose control and reduced glycaemic variability at weeks 4 and 10, as shown by reductions in 24‐hour glucose, FPG and PPG levels, MAGE and s.d., and increased time spent in euglycaemia.
- 1 May 2010
- Published by Elsevier in Journal of Dermatological Science
- Vol. 58 (2) , 113-122
The nuclear matrix shell proteome of human epidermis
- 1 May 2010
- Published by Elsevier in Journal of Dermatological Science
- Vol. 58 (2) , 113-122
The nuclear matrix shell proteome of human epidermis
- 1 November 2007
- Published by Radiation Research Society in Radiation Research
- Vol. 168 (5) , 535-544
Protein Phosphorylation in Irradiated Human Melanoma Cells
Warters, R. L., Williams, D. L., Zhuplatov, S. B., Pond, C. D. and Leachman, S. A. Protein Phosphorylation in Irradiated Human Melanoma Cells. Radiat. Res. 168, 535–544 (2007).In the present study, we examined the response of confluent, primary human fibroblasts and cells of a melanoma (YUSAC2) cell line to ionizing radiation mediated through post-translational protein phosphorylation. Since the purpose of our study was to identify novel radiation-induced phosphoproteins in the DNA damage stress response of melanoma cells, we were primarily interested in changes in protein phosphoserine expression at early times after irradiation. Our rationale was that by examining the overall protein phosphorylation profile (the phosphoproteome) in irradiated cells, we might discover novel radiation-induced phosphoproteins that distinguish fibroblasts from melanoma cells. Cell proteins were separated by gel electrophoresis and phosphoproteins were identified by Western blot analysis using nonspecific anti-phosphoamino acid antibodies. This approach was not pursued previously since adequate antibodies for examining global protein phosphoserine expression were unavailable. While some radiation-induced phosphoprotein changes in high-abundance proteins were identified, in general the sensitivity of this approach was not sufficient to detect changes in low-abundance, regulatory proteins. Characterization of these phosphoproteins will require greater enrichment of low-abundance proteins.
- 1 November 2007
- Published by Radiation Research Society in Radiation Research
- Vol. 168 (5) , 535-544
Protein Phosphorylation in Irradiated Human Melanoma Cells
Warters, R. L., Williams, D. L., Zhuplatov, S. B., Pond, C. D. and Leachman, S. A. Protein Phosphorylation in Irradiated Human Melanoma Cells. Radiat. Res. 168, 535–544 (2007).In the present study, we examined the response of confluent, primary human fibroblasts and cells of a melanoma (YUSAC2) cell line to ionizing radiation mediated through post-translational protein phosphorylation. Since the purpose of our study was to identify novel radiation-induced phosphoproteins in the DNA damage stress response of melanoma cells, we were primarily interested in changes in protein phosphoserine expression at early times after irradiation. Our rationale was that by examining the overall protein phosphorylation profile (the phosphoproteome) in irradiated cells, we might discover novel radiation-induced phosphoproteins that distinguish fibroblasts from melanoma cells. Cell proteins were separated by gel electrophoresis and phosphoproteins were identified by Western blot analysis using nonspecific anti-phosphoamino acid antibodies. This approach was not pursued previously since adequate antibodies for examining global protein phosphoserine expression were unavailable. While some radiation-induced phosphoprotein changes in high-abundance proteins were identified, in general the sensitivity of this approach was not sufficient to detect changes in low-abundance, regulatory proteins. Characterization of these phosphoproteins will require greater enrichment of low-abundance proteins.
- Open Access
- 27 November 2006
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 99 (6) , 431-439
Mechanism of Dipyridamole's Action in Inhibition of Venous and Arterial Smooth Muscle Cell Proliferation
Dipyridamole is a potential pharmacological agent to prevent vascular stenosis because of its antiproliferative properties. The mechanisms by which dipyridamole inhibits the growth of vascular smooth muscle cells, especially venous smooth muscle cells, are unclear. In the present study, dipyridamole transiently but significantly increased cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in human venous and arterial smooth muscle cells in a time‐ and dose‐dependent manner. Peak concentrations of both cyclic nucleotides were achieved at 15–30 min. and correlated with inhibition of proliferation in both cell types. The antiproliferative effects of dipyridamole observed at 48 hr were similar whether drug exposure was only 15 min. or sustained for 48 hr. Specific competitive inhibitors of protein kinases A and G attenuated the antiproliferative effects of subsaturating concentrations of dipyridamole, with the effects of protein kinase inhibition being particularly pronounced in venous smooth muscle cells. Flow cytometry analysis showed that dipyridamole caused an enrichment of cells in G0/G1 and a corresponding reduction of cells in S phase. These data indicate that a transient increase in cGMP and cAMP is sufficient to induce downstream kinase activation and subsequent cell cycle arrest, and that protein kinase G may be more important than protein kinase A in mediating the growth inhibitory effect of dipyridamole in venous protein kinase.
- 27 November 2006
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 99 (6) , 431-439
Open AccessMechanism of Dipyridamole's Action in Inhibition of Venous and Arterial Smooth Muscle Cell Proliferation
Dipyridamole is a potential pharmacological agent to prevent vascular stenosis because of its antiproliferative properties. The mechanisms by which dipyridamole inhibits the growth of vascular smooth muscle cells, especially venous smooth muscle cells, are unclear. In the present study, dipyridamole transiently but significantly increased cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in human venous and arterial smooth muscle cells in a time‐ and dose‐dependent manner. Peak concentrations of both cyclic nucleotides were achieved at 15–30 min. and correlated with inhibition of proliferation in both cell types. The antiproliferative effects of dipyridamole observed at 48 hr were similar whether drug exposure was only 15 min. or sustained for 48 hr. Specific competitive inhibitors of protein kinases A and G attenuated the antiproliferative effects of subsaturating concentrations of dipyridamole, with the effects of protein kinase inhibition being particularly pronounced in venous smooth muscle cells. Flow cytometry analysis showed that dipyridamole caused an enrichment of cells in G0/G1 and a corresponding reduction of cells in S phase. These data indicate that a transient increase in cGMP and cAMP is sufficient to induce downstream kinase activation and subsequent cell cycle arrest, and that protein kinase G may be more important than protein kinase A in mediating the growth inhibitory effect of dipyridamole in venous protein kinase.
- Open Access
- 1 June 2006
- Published by Elsevier in Kidney International
- Vol. 69 (12) , 2179-2185
Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis
- 1 June 2006
- Published by Elsevier in Kidney International
- Vol. 69 (12) , 2179-2185
Open AccessEfficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis
- Open Access
- 1 November 2004
- Published by Elsevier in Kidney International
- Vol. 66 (5) , 2061-2069
Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel
- 1 November 2004
- Published by Elsevier in Kidney International
- Vol. 66 (5) , 2061-2069
Open AccessInhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel
- 1 January 1994
- Vol. 66 (12) , 11-3
[The functional dynamics of capillary blood flow in patients with IHD combined with diabetes mellitus].
- 1 January 1994
- Vol. 66 (12) , 11-3
[The functional dynamics of capillary blood flow in patients with IHD combined with diabetes mellitus].
- 1 February 1990
- Vol. 30 (2) , 58-61
POSSIBILITIES OF HEMOSORPTION IN COMPENSATION OF CARDIAC DYSFUNCTION IN PATIENTS WITH IHD IN COMBINATION WITH DIABETES-MELLITUS
A total of 36 patients with unstable angina and type II diabetes mellitus were studied in the dynamic. All the patients underwent extracorporeal hemocarboperfusion. Marked improvement in the inotropic function of the myocardium was noted with the increase in the rate of relaxation and contraction of the posterior wall of the myocardium. A decrease in the pressure in the lesser circulation and specific peripheal resistance were registered. Using radiometry technique a corresponding decrease in the volume of extravascular fluid in the lungs was observed.
- 1 February 1990
- Vol. 30 (2) , 58-61
POSSIBILITIES OF HEMOSORPTION IN COMPENSATION OF CARDIAC DYSFUNCTION IN PATIENTS WITH IHD IN COMBINATION WITH DIABETES-MELLITUS
A total of 36 patients with unstable angina and type II diabetes mellitus were studied in the dynamic. All the patients underwent extracorporeal hemocarboperfusion. Marked improvement in the inotropic function of the myocardium was noted with the increase in the rate of relaxation and contraction of the posterior wall of the myocardium. A decrease in the pressure in the lesser circulation and specific peripheal resistance were registered. Using radiometry technique a corresponding decrease in the volume of extravascular fluid in the lungs was observed.